EGFR and neoplasm: Inactivation of MSMO1 or its partner NAD(P) dependent steroid dehydrogenase-like (NSDHL) sensitizes various tumor cell lines (such as A431, SCC61, SCC68, SCC25, PC9, FaDu, Detroit and MCF12F) to epidermal growth factor receptor (EGFR) inhibitors by promoting EGFR degradation via lysosomal trafficking.